Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and Gemcitabine in Previously
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Version: 3 Date: 04 Apr 2025
Reviewer's report:
No further comments.
Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and Gemcitabine in Previously
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Version: 3 Date: 04 Apr 2025
Reviewer's report:
No further comments.
Please review this paper.
user
Title: Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and Gemcitabine in Previously
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Version: 3 Date: 04 Apr 2025
Reviewer's report:
No further comments.
assistant